PeptiDream Signs a Multi-Target Collaboration and License Agreement with Genentech to Discover and Develop Novel Peptide-Radioisotope Drug Conjugates
- PeptiDream will receive $40M up front, ~$1B upon achievement of development, regulatory & commercial milestones along with royalties on net sales (ex-Japan) of any such products that emerge from the collaboration
- PeptiDream will get the right to develop & commercialize peptide-RI drug conjugate products in Japan & will be responsible for early preclinical development before transitioning peptide-RI drug conjugate products to Genentech for further development & commercialization
- The collaboration focuses on discovering, optimizing & developing macrocyclic peptide candidates for use as peptide-RI drug conjugates against targets of interest to Genentech using the Peptide Discovery Platform System technology
Ref: Businesswire | Image: Genentech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.